120 related articles for article (PubMed ID: 17095218)
21. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
Sawyer JS; Beight DW; Britt KS; Anderson BD; Campbell RM; Goodson T; Herron DK; Li HY; McMillen WT; Mort N; Parsons S; Smith EC; Wagner JR; Yan L; Zhang F; Yingling JM
Bioorg Med Chem Lett; 2004 Jul; 14(13):3581-4. PubMed ID: 15177479
[TBL] [Abstract][Full Text] [Related]
22. The development of monocyclic pyrazolone based cytokine synthesis inhibitors.
Golebiowski A; Townes JA; Laufersweiler MJ; Brugel TA; Clark MP; Clark CM; Djung JF; Laughlin SK; Sabat MP; Bookland RG; VanRens JC; De B; Hsieh LC; Janusz MJ; Walter RL; Webster ME; Mekel MJ
Bioorg Med Chem Lett; 2005 May; 15(9):2285-9. PubMed ID: 15837310
[TBL] [Abstract][Full Text] [Related]
23. Discovery and optimization of p38 inhibitors via computer-assisted drug design.
Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N
J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737
[TBL] [Abstract][Full Text] [Related]
24. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
[TBL] [Abstract][Full Text] [Related]
25. Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38.
Kamenecka T; Habel J; Duckett D; Chen W; Ling YY; Frackowiak B; Jiang R; Shin Y; Song X; LoGrasso P
J Biol Chem; 2009 May; 284(19):12853-61. PubMed ID: 19261605
[TBL] [Abstract][Full Text] [Related]
26. 1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.
Lumeras W; Vidal L; Vidal B; Balagué C; Orellana A; Maldonado M; Domínguez M; Segarra V; Caturla F
J Med Chem; 2011 Nov; 54(22):7899-910. PubMed ID: 21999461
[TBL] [Abstract][Full Text] [Related]
27. Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors.
Cirillo PF; Hickey ER; Moss N; Breitfelder S; Betageri R; Fadra T; Gaenzler F; Gilmore T; Goldberg DR; Kamhi V; Kirrane T; Kroe RR; Madwed J; Moriak M; Netherton M; Pargellis CA; Patel UR; Qian KC; Sharma R; Sun S; Swinamer A; Torcellini C; Takahashi H; Tsang M; Xiong Z
Bioorg Med Chem Lett; 2009 May; 19(9):2386-91. PubMed ID: 19356929
[TBL] [Abstract][Full Text] [Related]
28. Pyrroles and other heterocycles as inhibitors of p38 kinase.
de Laszlo SE; Visco D; Agarwal L; Chang L; Chin J; Croft G; Forsyth A; Fletcher D; Frantz B; Hacker C; Hanlon W; Harper C; Kostura M; Li B; Luell S; MacCoss M; Mantlo N; O'Neill EA; Orevillo C; Pang M; Parsons J; Rolando A; Sahly Y; Sidler K; O'Keefe SJ
Bioorg Med Chem Lett; 1998 Oct; 8(19):2689-94. PubMed ID: 9873604
[TBL] [Abstract][Full Text] [Related]
29. Benzodipyrazoles: a new class of potent CDK2 inhibitors.
D'Alessio R; Bargiotti A; Metz S; Brasca MG; Cameron A; Ermoli A; Marsiglio A; Polucci P; Roletto F; Tibolla M; Vazquez ML; Vulpetti A; Pevarello P
Bioorg Med Chem Lett; 2005 Mar; 15(5):1315-9. PubMed ID: 15713378
[TBL] [Abstract][Full Text] [Related]
30. Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.
Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Rucklin G
Bioorg Med Chem Lett; 2004 Jul; 14(13):3595-9. PubMed ID: 15177482
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and activity of a potent, selective series of N-aryl pyridinone inhibitors of p38 kinase.
Selness SR; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R; Devraj RV; Messing D; Schindler JF; Hirsch J; Saabye M; Bonar S; Webb E; Anderson G; Monahan JB
Bioorg Med Chem Lett; 2011 Jul; 21(13):4059-65. PubMed ID: 21640588
[TBL] [Abstract][Full Text] [Related]
32. Microwave-assisted synthesis of 5-aminopyrazol-4-yl ketones and the p38(MAPK) inhibitor RO3201195 for study in Werner syndrome cells.
Bagley MC; Davis T; Dix MC; Murziani PG; Rokicki MJ; Kipling D
Bioorg Med Chem Lett; 2008 Jul; 18(13):3745-8. PubMed ID: 18539026
[TBL] [Abstract][Full Text] [Related]
33. N-Phenyl-N-purin-6-yl ureas: the design and synthesis of p38alpha MAP kinase inhibitors.
Wan Z; Boehm JC; Bower MJ; Kassis S; Lee JC; Zhao B; Adams JL
Bioorg Med Chem Lett; 2003 Mar; 13(6):1191-4. PubMed ID: 12643941
[TBL] [Abstract][Full Text] [Related]
34. 3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead.
Soth M; Abbot S; Abubakari A; Arora N; Arzeno H; Billedeau R; Dewdney N; Durkin K; Frauchiger S; Ghate M; Goldstein DM; Hill RJ; Kuglstatter A; Li F; Loe B; McCaleb K; McIntosh J; Papp E; Park J; Stahl M; Sung ML; Suttman R; Swinney DC; Weller P; Wong B; Zecic H; Gabriel T
Bioorg Med Chem Lett; 2011 Jun; 21(11):3452-6. PubMed ID: 21515047
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
36. 2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations.
Ziegler K; Hauser DR; Unger A; Albrecht W; Laufer SA
ChemMedChem; 2009 Nov; 4(11):1939-48. PubMed ID: 19731280
[TBL] [Abstract][Full Text] [Related]
37. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
38. p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones.
Bao J; Hunt JA; Miao S; Rupprecht KM; Stelmach JE; Liu L; Ruzek RD; Sinclair PJ; Pivnichny JV; Hop CE; Kumar S; Zaller DM; Shoop WL; O'neill EA; O'keefe SJ; Thompson CM; Cubbon RM; Wang R; Zhang WX; Thompson JE; Doherty JB
Bioorg Med Chem Lett; 2006 Jan; 16(1):64-8. PubMed ID: 16242322
[TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.
Trejo A; Arzeno H; Browner M; Chanda S; Cheng S; Comer DD; Dalrymple SA; Dunten P; Lafargue J; Lovejoy B; Freire-Moar J; Lim J; Mcintosh J; Miller J; Papp E; Reuter D; Roberts R; Sanpablo F; Saunders J; Song K; Villasenor A; Warren SD; Welch M; Weller P; Whiteley PE; Zeng L; Goldstein DM
J Med Chem; 2003 Oct; 46(22):4702-13. PubMed ID: 14561090
[TBL] [Abstract][Full Text] [Related]
40. Displacement assay for the detection of stabilizers of inactive kinase conformations.
Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
